文献速递支持与姑息治疗

Quizartinib对比挽救性化疗治疗复发难治FLT3-ITD急性髓系白血病(QuANTUM-R):多中心随机对照开放标签3期试验

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2019-06-04

QuANTUM-R是一项在19国152中心开展的3期试验,367例复发难治FLT3-ITD阳性AML患者按2:1随机接受quizartinib或研究者选择的挽救性化疗。quizartinib安全性可控,或可成为新标准治疗。

要点

  • quizartinib组3级QT间期延长不常见(中心判读8例[3%]),无4级事件。

核心结论

  • 在复发难治FLT3-ITD阳性急性髓系白血病患者中,quizartinib较挽救性化疗具有生存获益且安全性可控。
  • quizartinib可考虑作为新的标准治疗,尤其鉴于可用治疗选择有限。

研究设计与样本

  • QuANTUM-R为随机、对照、开放标签、3期试验,在19个国家152家医院和癌症中心开展。
  • 纳入367例年龄≥18岁、ECOG 0-2、复发难治(首次复合完全缓解持续时间≤6个月)FLT3-ITD阳性AML患者。
  • 患者按2:1随机分配至quizartinib组(245例)或研究者选择的挽救性化疗组(122例),按既往治疗反应和化疗选择分层。

主要发现

  • quizartinib组(241例)与化疗组(94例)最常见的3-5级非血液学治疗中出现的不良事件为脓毒症或脓毒性休克(46例[19%] vs 18例[19%])、肺炎(29例[12%] vs 8例[9%])和低钾血症(28例[12%] vs 8例[9%])。
  • quizartinib组治疗相关严重不良事件最常见为发热性中性粒细胞减少(18例[7%])、脓毒症或脓毒性休克(11例[5%])、QT间期延长(5例[2%])和恶心(5例[2%])。
  • quizartinib组3级QT间期延长不常见(中心判读8例[3%],研究者报告10例[4%]),无4级事件;治疗中出现的死亡80例(33%),其中31例(13%)归因于不良事件。

临床怎么用

  • 对于复发难治FLT3-ITD阳性AML患者,可考虑使用quizartinib 60 mg(30 mg导入)口服每日一次作为挽救治疗。
  • 治疗期间需监测QT间期延长等不良事件,但3级QT延长发生率较低且无4级事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with relapsed or refractory FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of relapse, poorer response to salvage therapy, and shorter overall survival than those with FLT3 wild-type disease. We aimed to assess whether single-agent quizartinib, an oral, highly potent and selective type II FLT3 inhibitor, improves overall survival versus salvage chemotherapy. METHODS: QuANTUM-R is a randomised, controlled, phase 3 trial done at 152 hospitals and cancer centres in 19 countries. Eligible patients aged 18 years or older with ECOG performance status 0-2 with relapsed or refractory (duration of first composite complete remission ≤6 months) FLT3-ITD acute myeloid leukaemia after standard therapy with or without allogeneic haemopoietic stem-cell transplantation were randomly assigned (2:1; permuted block size of 6; stratified by response to previous therapy and choice of chemotherapy via a phone-based and web-based interactive response system) to quizartinib (60 mg [30 mg lead-in] orally once daily) or investigator's choice of preselected chemotherapy: subcutaneous low-dose cytarabine (subcutaneous injection of cytarabine 20 mg twice daily on days 1-10 of 28-day cycles); intravenous infusions of mitoxantrone (8 mg/m2 per day), etoposide (100 mg/m2 per day), and cytarabine (1000 mg/m2 per day on days 1-5 of up to two 28-day cycles); or intravenous granulocyte colony-stimulating factor (300 μg/m2 per day or 5 μg/kg per day subcutaneously on days 1-5), fludarabine (intravenous infusion 30 mg/m2 per day on days 2-6), cytarabine (intravenous infusion 2000 mg/m2 per day on days 2-6), and idarubicin (intravenous infusion 10 mg/m2 per day on days 2-4 in up to two 28-day cycles). Patients proceeding to haemopoietic stem-cell transplantation after quizartinib could resume quizartinib after haemopoietic stem-cell transplantation. The primary endpoint was overall survival in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT02039726, and follow-up is ongoing. FINDINGS: Between May 7, 2014, and Sept 13, 2017, 367 patients were enrolled, of whom 245 were randomly allocated to quizartinib and 122 to chemotherapy. Four patients in the quizartinib group and 28 in the chemotherapy group were not treated. Median follow-up was 23·5 months (IQR 15·4-32·3). Overall survival was longer for quizartinib than for chemotherapy (hazard ratio 0·76 [95% CI 0·58-0·98; p=0·02]). Median overall survival was 6·2 months (5·3-7·2) in the quizartinib group and 4·7 months (4·0-5·5) in the chemotherapy group. The most common non-haematological grade 3-5 treatment-emergent adverse events (within ≤30 days of last dose or >30 days if suspected to be a treatment-related event) for quizartinib (241 patients) and chemotherapy (94 patients) were sepsis or septic shock (46 patients [19%] for quizartinib vs 18 [19%] for chemotherapy), pneumonia (29 [12%] vs eight [9%]), and hypokalaemia (28 [12%] vs eight [9%]). The most frequent treatment-related serious adverse events were febrile neutropenia (18 patients [7%]), sepsis or septic shock (11 [5%]), QT prolongation (five [2%]), and nausea (five [2%]) in the quizartinib group, and febrile neutropenia (five [5%]), sepsis or septic shock (four [4%]), pneumonia (two [2%]), and pyrexia (two [2%]) in the chemotherapy group. Grade 3 QT prolongation in the quizartinib group was uncommon (eight [3%] by central reading, ten [4%] by investigator report); no grade 4 events occurred. There were 80 (33%) treatment-emergent deaths in the quizartinib group (31 [13%] of which were due to adverse events) and 16 (17%) in the chemotherapy group (nine [10%] of which were due to adverse events). INTERPRETATION: Treatment with quizartinib had a survival benefit versus salvage chemotherapy and had a manageable safety profile in patients with rapidly proliferative disease and very poor prognosis. Quizartinib could be considered a new standard of care. Given that there are only a few available treatment options, this study highlights the value of targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor. FUNDING: Daiichi Sankyo.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019. PMID: 31175001. doi:10.1016/S1470-2045(19)30150-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。